THG-1/TSC22D4 Promotes IL-1 Signaling through Stabilization of TRAF6 in Squamous Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Chronic inflammation is a critical driver of tumorigenesis, influencing all stages of cancer development.
• Interleukin-1 (IL-1) signaling plays a significant role in tumor progression, but its continuous activation mechanism in tumors remains unclear.
• Squamous cell carcinoma (SCC) is a type of cancer where understanding inflammatory pathways is crucial for treatment.

Purpose of the Study:

• To elucidate a novel mechanism for the autocrine activation of IL-1 signaling in SCC.
• To investigate the role of the oncoprotein TSC-22 homologous gene-1 (THG-1, also known as TSC22D4) in regulating inflammatory pathways in SCC.
• To explore the potential of THG-1 as a therapeutic target or diagnostic marker for SCC.

Main Methods:

• RNA sequencing analysis to identify THG-1's transcriptional targets.
• Knockdown experiments to assess the impact of THG-1 on IL-1 responsiveness and NF-κB signaling.
• Co-immunoprecipitation and Western blotting to study protein interactions and degradation pathways, focusing on NRBP1 and TRAF6.
• Analysis of public databases and patient specimens (laryngeal SCC) to correlate THG-1 expression with pathway activation and clinical outcomes.

Main Results:

• THG-1 overexpression upregulates key NF-κB target genes, including IL1A, IL1B, TNFA, and IL8, promoting inflammation.
• THG-1 interacts with NRBP1, inhibiting the E3 ubiquitin ligase activity of NRBP1 and consequently suppressing the degradation of TRAF6.
• High THG-1 expression in head and neck SCC correlates with activated IL-1 and TNF signaling pathways, which converge on TRAF6.
• Elevated THG-1 levels in laryngeal SCC specimens are associated with patient recurrence, suggesting its role in disease progression.

Conclusions:

• THG-1 establishes a self-sustaining IL-1-mediated inflammatory loop in SCC by stabilizing TRAF6.
• This mechanism of continuous inflammation driven by THG-1 contributes to SCC progression and recurrence.
• THG-1 represents a potential biomarker for SCC diagnosis and a promising target for novel immunotherapies.